Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
FI: 4,981
Type: Article
Collaboration
Year: 2021
Writers
Facey, KM; Espín, J; Kent, E.; Link, A; Nicod, E; O'Leary, A; Xoxi, E; van de Vijver, I; Zaremba, A; Benisheva, T.; Vagoras, A; Upadhyaya, S.
Magazine
Title: PHARMACOECONOMICS
Quartile
- D1